← Back to Home

A New Seam Emerges in Cancer Cells’ Signaling Switch: Asymmetric BRAF Structure Points to Another Drug-Targeting Route

Researchers have captured a previously unseen working conformation of BRAF as it activates MEK1, providing a more detailed blueprint for bypassing existing drug resistance; however, the findings remain at the structural and cellular levels, with multiple hurdles still standing between them and a drug candidate.

By SURL BioNews

Many anticancer drugs fail not because they initially miss their target, but because cancer cells gradually find ways around them. A team from the Paul Scherrer Institute (PSI) in Switzerland and the University of Zurich has now uncovered a new conformation adopted by BRAF as it transmits growth signals, allowing researchers to see for the first time how this molecular machinery fits together while operating—and revealing a new interface that may be amenable to drug intervention.

BRAF is a signaling protein that controls cell growth and division. Under normal circumstances, it activates downstream pathways only after receiving upstream instructions; certain mutations, however, can leave the switch permanently in the “on” position, continually driving cell proliferation. PSI noted that BRAF mutations occur in about half of melanomas and around 7% of other cancers. Although existing targeted therapies can suppress some tumors, drug resistance often limits how long their effects last.

The study, published in *Molecular Cell*, shows that two BRAF molecules do not always adopt the same posture when they bind. The team resolved a previously unknown asymmetric dimer: two differently shaped BRAF molecules sit side by side, with the N-terminal acidic sequence (NtA) of one molecule extending toward the other and stabilizing the entire assembly like a bridge. This finding places the NtA segment, previously known to be associated with BRAF activation, within a more complete three-dimensional context of interaction.

More importantly, the researchers did not observe BRAF alone; they captured a complex in which it was connected to the downstream protein MEK1 and poised to transmit a signal. The team used PSI’s Swiss Light Source and the UK’s Diamond Light Source to study the molecular structure, and conducted experiments in human cells at the University of Zurich to examine the relationship between this asymmetric assembly and MEK1 activation. The structural data and cellular evidence reinforce each other, indicating that this is not merely a protein conformation that appeared by chance in a test tube.

The pharmacological possibility raised by this structural map is to move beyond suppressing BRAF only at existing sites and instead seek molecules that can lock the new complex in place, disrupt the NtA bridge, or prevent the subsequent activation of MEK1. If a different mechanism of action can be established, it may in the future expand treatment options for BRAF-driven tumors and provide an alternative route in some drug-resistance settings. The PSI team has begun screening for compounds that can bind to this BRAF–MEK1 complex and interrupt the signal.

However, the fact that a new pocket or protein interface “can be seen” does not mean it has been shown to be “druggable.” The information currently available has not identified a specific candidate molecule, demonstrated efficacy in animal tumors, defined a toxicity range, or reported human trial results. Nor has it shown which clinical drug-resistance mechanisms could be overcome by targeting this conformation. Beyond identifying compounds with sufficient binding affinity and selectivity, the next steps must determine whether this complex is broadly present across different BRAF mutations and cancer types, and whether blocking it would interfere with growth signals essential to normal cells.

References

  1. Paul Scherrer Institute
  2. Paul Scherrer Institute